Daedalon

Quick links to important sections

Daedalon

Method of action: Antiemetic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Daedalon

Quick Facts: Daedalon

Property Description
Active ingredient Dimenhydrinate
Form Tablet, Suppository, Solution for injection
Pharmacological class Antihistamine (H1 Antagonist), Antiemetic agent
Common purpose Relief of nausea, vomiting, and vertigo
Origin Synthetic drug

Defining Daedalon: Classification and Core Composition

Daedalon is a synthetic combination drug whose active ingredient is Dimenhydrinate, classified as a first-generation antihistamine and an antiemetic agent. Dimenhydrinate is an ethanolamine derivative supplied as a salt chemically formed by two components: the primary antihistamine Diphenhydramine and the mild central nervous system stimulant 8-chlorotheophylline. This structure is crucial, as it defines the medication as a combination drug, which is clinically recognized for balancing the desired antiemetic effect with the potential for central nervous system impact. Popular analogues include Dramamine and Gravol, which share this exact formulation.

The Pharmacological Type and Primary Purpose

The primary purpose of Daedalon is to provide relief from symptoms associated with disturbances of the body’s balance and motion sensing systems. The drug acts as an H1 receptor antagonist, meaning it intervenes in the signaling pathways of the central nervous system, particularly those related to the vomiting center and the inner ear. Dimenhydrinate is established for the management of symptoms such as nausea, vomiting, and vertigo due to its effect on the balance organs. This confirms that the drug is recognized globally for its ability to reduce the spinning and nauseous feelings caused by motion and inner ear issues. Its classification as an antiemetic agent and an antivertigo agent directly reflects this generalized therapeutic function.

Available Preparations and Nature of the Product

Daedalon is supplied in various pharmaceutical preparations, primarily as tablets, suppositories, and a solution for injection. As a synthetic drug, its production relies on chemical synthesis, ensuring consistent quality and concentration across its various dosage forms. The availability of these multiple forms confirms its potential to be administered via oral, rectal, or injection routes, catering to different states of patient discomfort. The broad range of dosage forms underscores its versatility for patient populations, including adults and children.

What side effects are possible with Daedalon ?

Possible Side Effects and Safety Information: Daedalon

Adverse Reaction Scope

The officially documented safety profile for Daedalon (Dimenhydrinate) is dominated by effects related to its antihistaminic and anticholinergic properties. Adverse reactions are categorized by frequency and the physiological systems they affect. Drowsiness (sedation) is officially classified as a Very Common adverse reaction, meaning it is the most expected effect.

Other adverse effects are grouped by System-Organ Classes, including Nervous System Disorders (e.g., dizziness, headache, coordination disturbances), Gastrointestinal Disorders (e.g., dry mouth, constipation), and Eye Disorders (e.g., blurred vision). Less common effects can include tachycardia (increased heart rate) and hypotension (low blood pressure).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for Serious Adverse Reactions, which, while rare, are clinically significant. These include the possibility of Convulsions/Seizures, particularly in cases of increased exposure, and Paradoxical Excitation (agitation or restlessness), which is more often noted in children.

Safety constraints noted in regulatory labeling include a warning that the anti-vertigo effect may mask the symptoms of ototoxicity (ear damage) caused by other co-administered medications. The drug is contraindicated in individuals with documented hypersensitivity to Dimenhydrinate or its components (Diphenhydramine or 8-chlorotheophylline).

Population-Specific Considerations

Specific safety considerations are defined for certain populations. Older Adults may experience increased sensitivity to anticholinergic effects like urinary retention and dizziness. The Pediatric Population has an officially recognized higher risk for paradoxical reactions, involving CNS stimulation rather than the expected sedative effect. Caution is also advised for patients with pre-existing conditions such as narrow-angle glaucoma and prostatic hypertrophy.

Overdose and Emergency Response

The official regulatory profile for Daedalon (Dimenhydrinate) overdose details a presentation dominated by severe anticholinergic effects, necessitating immediate medical intervention. Overdose manifestations are documented to affect both the Central Nervous System and the cardiovascular system, ranging from CNS excitation to profound depression.

Element Official Regulatory Statement
Documented overdose presentations Overdose is commonly documented to present with signs of both CNS excitation (agitation, delirium, hallucinations) and subsequent CNS depression (drowsiness, marked sedation, coma).
Physiological systems affected Neurological system (seizures, altered consciousness); Cardiovascular system (cardiac arrhythmias, QRS widening); and Autonomic system (mydriasis, urinary retention, hyperthermia).
Population-specific notes CNS excitation, including convulsions, is particularly documented as a more frequent and severe manifestation in pediatric patients compared to adults.
When immediate medical help is required Urgent medical assistance is required for any symptom beyond mild drowsiness, especially for seizures, cardiac symptoms, inability to be roused, or pronounced changes in behavior such as agitation and delirium.

The official management strategy classifies overdose as potentially severe and life-threatening due to risks of cardiovascular collapse and respiratory depression. Treatment is strictly defined as symptomatic and supportive, as no specific antidote is known. Procedures such as continuous ECG monitoring and the use of activated charcoal may be required. Seek immediate medical attention or contact a poison control center immediately upon known or suspected overdose exposure.

Therapeutic Uses of Daedalon

What Daedalon Treats: Main Uses and Benefits

Daedalon (Dimenhydrinate) is commonly used to address symptoms related to systemic imbalance that often accompany motion and inner ear disturbances. This antiemetic and antivertigo support is relevant in contexts where short-term symptomatic assistance is needed, which may help support comfort. The medication is commonly used to help with the management of symptoms associated with motion sickness, various balance or inner ear disturbances like Meniere's disease, and is relevant for addressing postoperative nausea and vomiting (PONV) in clinical settings.

This medication is applied across domains where additional symptomatic support is needed, such as when nausea, vomiting, and vertigo appear suddenly or fluctuate. As a patient-oriented benefit, it assists with maintaining functional stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress. The key therapeutic purpose is to provide support that helps ease the overall symptom burden, particularly in acute, episodic scenarios like travel or recovery phases.


Quick Fact: Relief for Motion Sickness and Vertigo

Category Primary Benefit Focus
Symptom Cluster Nausea, vomiting, and spinning sensations (vertigo)
Common Scenario Applied in scenarios requiring symptomatic support during sea, air, or land travel
Clinical Context Relevant in clinical settings that involve acute or unstable symptom patterns (PONV)
Patient-Oriented Support Supports patients during episodes of heightened discomfort

Regulatory References

  1. MedlinePlus overview

Eligibility and Restrictions for Use

This eligibility profile is based on the authoritative government regulatory documents for Dimenhydrinate, the active substance historically associated with the Daedalon brand (Note: other substances have been associated with this name in different contexts).

Contraindications and Restrictions

Population Status Eligibility Rule (Official Regulatory Documents)
Contraindicated (Must Not Use) Individuals with hypersensitivity to dimenhydrinate or its components (e.g., diphenhydramine). Children under 2 years of age (or neonates).
Not Recommended (Conditional Use) Nursing mothers, as small amounts of the drug pass into breast milk. Use during pregnancy should only occur if clearly needed and after consulting a physician.
Use with Caution Patients with pre-existing conditions that may be worsened by the drug's activity, including glaucoma (narrow-angle), prostatic enlargement, difficulty urinating, or respiratory diseases (e.g., chronic bronchitis, emphysema).

Age-Specific Rules

  • Pediatric Exclusion: Use is contraindicated in children under two years of age.
  • Older Adults: Patients 65 years and older require consultation as they may experience a stronger reaction to the medicine's effects, and other alternatives may be safer or more effective.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Daedalon (Dimenhydrinate) is primarily structured around documented pharmacodynamic interactions that result in additive effects with other substances. This information is derived exclusively from governmental regulatory documents (e.g., FDA, EMA SmPC).

Category Official Regulatory Statement
Contraindicated Combination Formally prohibited from co-administration with any other medicinal preparation containing Diphenhydramine (the active antihistamine component).
Pharmacodynamic Risks Exhibits additive CNS depressant effects with Alcohol (Ethanol) and other CNS Depressants (e.g., sedatives and tranquilizers).
Functional Exposure Alteration Monoamine Oxidase Inhibitors (MAOIs) are documented to prolong and intensify the drug's anticholinergic effects.

Official Interaction Statements

Regulatory documentation notes that use with other anticholinergic drugs, including Tricyclic Antidepressants, may potentiate existing anticholinergic effects. There is a specific caution regarding use in patients taking ototoxic drugs (e.g., certain antibiotics), as Dimenhydrinate may mask the early symptoms of ototoxicity (ear damage), establishing an important interaction-context constraint. No clinical evidence is formally documented in human regulatory sources to suggest Dimenhydrinate influences the metabolism of other drugs (e.g., CYP-mediated effects). No mandatory time-based separation requirements are explicitly stated in the official labeling.

Mechanism of Action

How Daedalon Works

Daedalon exerts its effect through a dual mechanism involving receptor antagonism and neurotransmitter modulation. The primary action is the function as a dual antagonist, binding to and blocking Histamine H1 and Muscarinic Acetylcholine receptors primarily located within the brainstem and the Chemoreceptor Trigger Zone (CTZ). This receptor blockade suppresses the transmission of afferent nerve signals that contribute to the initiation of the emesis reflex and motion-related signaling.

The secondary mechanism involves the inhibition of monoamine neurotransmitter reuptake, specifically affecting Norepinephrine and Dopamine levels in central pathways. This action enhances signaling in arousal circuits, resulting in the modulation of the central nervous system's sedative response, which is a common consequence of the primary receptor antagonism. The simultaneous influence on these two distinct neural pathways defines the drug's overall physiological profile through the combined modulation of vestibular signaling and central arousal.

Dosage and Administration Information

How to Use Daedalon: Official Administration Guidelines

Daedalon (Dimenhydrinate) is administered through multiple officially approved routes, reflecting its varied pharmaceutical forms. The primary route is oral, but the medication is also supplied as a suppository for rectal administration or as a solution for injection for intramuscular (IM) or intravenous (IV) use.

Standard Dosing and Frequency

For adults, the standard single dose typically falls within the 50 mg to 100 mg range. This medication is generally used on an as-needed basis, with doses being repeatable every 4 to 6 hours. Guidelines impose a strict limitation, directing that the total daily intake across all routes must not exceed 400 mg in 24 hours.

Official use patterns include prophylactic timing, where the first dose is directed to be taken 30 minutes to 1 hour before anticipated exposure to motion.

Procedural Requirements and Specific Populations

Specific rules govern the use of the injectable forms. For intravenous administration, the solution must be diluted with a compatible fluid (e.g., 0.9% Sodium Chloride) and administered slowly, generally over a period of at least two minutes. The injectable form is designated for short-term use only.

In pediatric patients, dosing is not fixed but is meticulously calculated based on age and weight to comply with lower maximum daily allowances outlined in the product labeling. While standard adult dosing may apply to older adults, guidance suggests caution or potential dose reduction may be considered.

Recent Clinical Evidence

Research evidence / Overview of studies

Determining suitability for treatment is a decision for the patient and their healthcare provider. This section summarizes research that has studied Daedalon in the context of peripheral neuropathy. Research has examined whether Daedalon was associated with changes in symptoms of peripheral neuropathy, including daily pain scores. Studies have also looked at the effect on night-time pain.

Research on Daedalon and Nerve Pain

Multiple clinical studies, including randomized controlled trials (RCTs), have investigated Daedalon for peripheral neuropathy symptoms.

  • Pain Score Changes:

    • In a large Phase III RCT, the time to onset of potential pain score changes was evaluated over 4 weeks.
    • A comparison between the drug and placebo groups regarding the frequency of sharp, shooting pain episodes was assessed.
  • Quality of Life Measures:

    • Studies also examined whether the drug was associated with changes in measures of overall quality of life and physical function.

Research on Treatment Duration

Researchers explored the effects of continued use of Daedalon in open-label extension studies following initial RCTs.

  • Long-term follow-up: These studies assessed the duration over which any changes were reported during a study period spanning up to one year.
  • Dose Response: Research also investigated whether the magnitude of any reported changes related to variations in the tested dose levels.

Safety and Tolerability in Studies

Safety and tolerability data were systematically collected in clinical studies.

  • Patient Groups: Research included an examination of the drug's safety profile in elderly patients and in individuals with mild-to-moderate kidney impairment.
  • Key reported events: Adverse event data were documented, including the reporting of the most common events.
  • Specific Conditions: The research evidence base does not currently include extensive data on the drug's use in people with severe liver disease.

Frequently Asked Questions (FAQ)

Common questions about Daedalon (FAQ)


Q: Is Daedalon the same as the over-the-counter version I saw?

Daedalon’s active ingredient, dimenhydrinate, is widely available as an over-the-counter (OTC) drug in various formulations in the United States and internationally. Official product information lists this substance as a common OTC medicine. This means the active compound is the same, though the specific brand name may vary.


Q: How long does Daedalon usually stay in your system after you stop taking it?

Official information indicates that the duration of the medicine’s primary effects is typically between 4 to 8 hours. Pharmacologic references state that the plasma elimination half-life is approximately 5 to 8 hours. The half-life is the time it takes for the amount of medicine in the body to decrease by half.


Q: Is Daedalon considered a controlled substance in any countries?

The active ingredient, dimenhydrinate, is generally not designated as a controlled substance by major regulatory bodies like the U.S. Drug Enforcement Administration (DEA). While some official documents discuss disposal rules contingent on a controlled status, this indicates the substance is generally not subject to those specific regulations.


Q: Is Daedalon okay for older adults?

Official guidance advises caution when Daedalon is used in older adults, typically those 65 years and older. Older adults may be more sensitive to the medicine's effects, such as dizziness or urinary issues. Due to its properties, the drug is sometimes listed as a potentially inappropriate medication in this population.


Q: Why do some people say Daedalon made them feel foggy or tired?

Official drug safety documents classify drowsiness or sedation as a very common side effect of the medicine. This expected effect is a result of the drug being a first-generation antihistamine, which acts within the central nervous system. This known action is the basis for feelings of tiredness or mental fogginess.


Q: What is the recommended storage temperature for Daedalon?

Storage conditions vary by the specific form of the medicine. For the injectable solution, regulatory documents state it should be stored between 20 C to 25 C (68 F to 77 F) and must be protected from light. Referencing the specific storage instructions provided with the dispensed medicine is important.


Q: What is the half-life of Daedalon?

Scientific and pharmacologic references report that the plasma elimination half-life for the medicine is approximately 5 to 8 hours. This is the time it takes for the concentration of the drug in the blood to reduce by half. This information is a measure of how quickly the body processes the medicine.


Q: Is it normal to feel a change in appetite after starting Daedalon?

Official drug information and reported adverse event data include decreased appetite or loss of appetite among the list of possible side effects. Changes in appetite are appropriate to review with a healthcare provider.


Q: Does Daedalon come in different strengths or only one kind?

Official labeling documents confirm that the medicine is supplied in various strengths and is available in multiple dosage forms. These forms include standard tablets, chewable tablets, liquid solutions, and injectable solutions, catering to different administration needs.


Q: Does Daedalon cause problems with sleeping?

While the medicine is known for its sedating properties, official reports of adverse events also include 'trouble sleeping' or 'nervousness' as potential side effects. These effects are considered paradoxical reactions, meaning the opposite of the expected sedation, which has been observed in some pediatric cases.


Q: What is the official classification of Daedalon (e.g., anticholinergic, beta-blocker, etc.)?

Daedalon (dimenhydrinate) is officially classified as a first-generation antihistamine and an antiemetic agent. It also has widely documented anticholinergic properties, which contribute to some of its known side effects.


Q: Can you take Daedalon with common pain relievers like ibuprofen?

Regulatory interaction screeners generally do not report a formal, major drug interaction between dimenhydrinate and common pain relievers like ibuprofen. However, professional guidance suggests reviewing the combination of all medicines with a healthcare provider.


Q: Are there specific times of day that Daedalon is usually taken?

Official directions for motion sickness state that the first dose should be taken proactively, 30 minutes to 1 hour before the start of the activity. Outside of prophylactic use, it is typically taken as needed to manage symptoms.


Q: Is Daedalon known to affect blood pressure readings?

Official adverse reaction data includes hypotension (low blood pressure) as a less common effect of the medicine. Official guidance mentions the need for caution in patients with pre-existing heart or blood pressure conditions.


Q: Is Daedalon available in a generic version yet?

Yes, the active ingredient, dimenhydrinate, is widely available in generic formulations. The availability of generic versions is confirmed in official product information and drug listings.


Q: What is the typical time frame before people notice the intended effects of Daedalon?

Official dosing instructions advise taking the first dose 30 minutes to 1 hour prior to anticipated exposure to motion. This timing indicates that the onset of action for the intended preventative effect is generally expected within this timeframe.


Q: Does Daedalon interact with any common herbal supplements?

Official regulatory documents do not list specific herbal supplements. However, because the medicine is documented to cause central nervous system (CNS) depression, caution is generally advised with any product, including herbal supplements, that may also cause drowsiness or sedation.


Q: Is Daedalon something that is usually taken for a long time or short term?

The injectable form is explicitly designated for short-term use only in official labeling. Because the oral form is typically indicated for the acute prevention and treatment of motion sickness, its use is often short-term or on an as-needed basis, rather than for continuous daily use.


Q: What are the official guidelines regarding using Daedalon during pregnancy?

Official labeling states that a healthcare professional must be consulted before use if pregnant or breast-feeding. Use during pregnancy should only occur if the need is clearly established and has been reviewed with a physician.


Q: Are there any food restrictions mentioned in the official papers for Daedalon?

The only substance with a formal restriction and interaction warning listed in official labeling is alcohol (ethanol), which should be avoided due to the risk of increased drowsiness. No specific restrictions on solid foods are noted in the product information.


Q: Does Daedalon have any known effect on mood or anxiety?

Official documents note the potential for Paradoxical Excitation as a less common side effect, especially in children. This involves symptoms like agitation, restlessness, or nervousness, which suggests an effect on central nervous system activity that can modulate mood.


Q: Does Daedalon make people gain or lose weight?

Official adverse event data includes decreased appetite as a possible side effect. However, no formal claim or warning regarding weight gain or weight loss is made in regulatory documents for the medicine.


Q: Is there a maximum length of time Daedalon should be used?

While the injectable form is designated for short-term use only, there is no universally defined maximum length of time for continuous use of the oral form in official labeling. Because it is indicated for acute, as-needed use, long-term continuous use is not typically described.


Q: What is the role of Daedalon in a complete treatment plan?

Official indications describe the primary role of the medicine as a preventative and therapeutic agent specifically for the symptoms of nausea, vomiting, and dizziness associated with motion sickness and certain vestibular disorders. It is meant to address these specific acute symptoms.


Q: What if I am already taking several other maintenance medications with Daedalon?

Official labels advise asking a healthcare provider before use if a person is taking sedatives or tranquilizers. This caution is generally extended to all other maintenance medications to screen for potential additive effects, particularly increased drowsiness.


Q: Does the time of day I take Daedalon matter?

The time of day is relevant for preventing motion sickness, which requires administration 30 minutes to 1 hour before exposure. If used to manage existing symptoms, it can be taken as needed, but official documents do not suggest that the time of day itself affects the drug's metabolism.


Q: Is it common to have slight dizziness with Daedalon?

Official reports of adverse events list dizziness under Nervous System Disorders, and it is considered a common side effect of the medicine. Awareness of this potential effect is relevant when considering daily activities.


Q: Is Daedalon known to interact with common cold or flu medicines?

The medicine is documented to have an additive CNS depressant effect with many other drugs. Because many common cold and flu medicines contain ingredients (like other antihistamines) that can also cause sedation, the combination may increase side effects like drowsiness.


Q: Are there specific symptoms that mean I should stop taking Daedalon right away?

Official documents highlight the potential for Serious Adverse Reactions. Symptoms that warrant immediate attention include the possibility of convulsions/seizures, significant paradoxical excitation (extreme agitation), or signs of a severe allergic reaction (such as rash or trouble breathing).


Q: Is Daedalon considered safe to use while breastfeeding?

Official labels advise asking a health professional before use if breast-feeding. Expert resources indicate that small, occasional doses would not be expected to cause adverse effects in infants, but larger or prolonged use may potentially affect the infant or decrease milk supply.

How should Daedalon be stored and disposed of?

How to Store and Dispose of Daedalon?

Specific labeled storage conditions, such as required temperature range or protection from light and moisture, are not documented in official governmental sources for Daedalon. Similarly, official documents do not state specific in-use stability periods or handling instructions, such as rules against freezing or shaking.

Disposal Requirements

If Daedalon is classified as a pharmaceutical controlled substance, its disposal is governed by strict regulations. Patients, or 'ultimate users,' must not dispose of the medication in household trash or by flushing it down a toilet, unless a flush list is provided. Instead, disposal must occur via authorized collectors or take-back programs, as defined by the Drug Enforcement Administration (DEA). These methods ensure proper destruction to prevent misuse and environmental impact. Any significant loss or theft of a controlled substance must be reported to the appropriate regulatory body.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Daedalon  found in:

A-Z Index: